Src tyrosine kinase inhibits apoptosis through the Erk1/2-dependent degradation of the death accelerator Bik

Cell Death and Differentiation

Volumn 19, Issue 9, 2012, Pages 1459-1469

  Lopez, J ^a,b   Hesling, C ^a   Prudent, J ^a   Popgeorgiev, N ^a   Gadet, R ^a   Mikaelian, I ^a   Rimokh, R ^a   Gillet, G ^a   Gonzalo, P ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CROIX ROUSSE HOSPITAL   (France)

Author keywords

apoptosis; Bik; Bim; Erk1 2; proteasome; Src

Indexed keywords

BIK PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEASOME; PROTEIN; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; STAUROSPORINE; THAPSIGARGIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; FIBROBLAST; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; MITOCHONDRIAL PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS; NIH 3T3 CELLS; ONCOGENE PROTEIN P21(RAS); PROTEOLYSIS; RAF KINASES; SRC-FAMILY KINASES; STAUROSPORINE; THAPSIGARGIN;

EID: 84865200796     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.21     Document Type: Article

References (39)

1. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001; 2: 467-475.
2. Takeya T, Hanafusa H. Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus. Cell 1983; 32: 881-890. (Pubitemid 13087937)
3. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993; 91: 53-60. (Pubitemid 23037252)
4. Zhang S, Huang W-C, Li P, Guo H, Poh S-B, Brady SW et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17: 461-469.
5. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
6. Clark W, Gillespie DA. Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors. Cell Growth Differ 1997; 8: 371-380. (Pubitemid 27273074)
7. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000; 103: 321-330.
8. Shan B, Lee WH. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 1994; 14: 8166-8173. (Pubitemid 24373565)
9. Sovová V, Friis R, Fidlerová H, Hlozánek I. c-myc gene activation as a permanent trait of RSV-infected quail cells. Int J Cancer 1993; 53: 983-987. (Pubitemid 23119548)
10. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424-2433. (Pubitemid 28371361)
11. Pasteau S, Loiseau L, Brun G. Proliferation of chicken neuroretina cells induced by v-src, in vitro, depends on activation of the E2F transcription factor. Oncogene 1997; 15: 17-28. (Pubitemid 27348093)
12. Reginato MJ, Mills KR, Becker EBE, Lynch DK, Bonni A, Muthuswamy SK et al. Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol 2005; 25: 4591-4601. (Pubitemid 40705763)
13. Gillet G, Guerin M, Trembleau A, Brun G. A Bcl-2-related gene is activated in avian cells transformed by the Rous sarcoma virus. EMBO J 1995; 14: 1372-1381.
14. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science 1999; 286: 1358-1362.
15. Webb BL, Jimenez E, Martin GS. v-Src generates a p53-independent apoptotic signal. Mol Cell Biol 2000; 20: 9271-9280. (Pubitemid 32248740)
16. Johnson D, Agochiya M, Samejima K, Earnshaw W, Frame M, Wyke J. Regulation of both apoptosis and cell survival by the v-Src oncoprotein. Cell Death Differ 2000; 7: 685-696. (Pubitemid 30599249)
17. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001; 20: 7779-7786. (Pubitemid 33121951)
18. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619-628. (Pubitemid 26386936)
19. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321. (Pubitemid 28524494)
20. Alvarado-Kristensson M, Melander F, Leandersson K, Rönnstrand L, Wernstedt C, Andersson T. p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med 2004; 199: 449-458. (Pubitemid 38233829)
21. Lucken-Ardjomande S, Montessuit S, Martinou J-C. Bax activation and stress-induced apoptosis delayed by the accumulation of cholesterol in mitochondrial membranes. Cell Death Differ 2008; 15: 484-493. (Pubitemid 351267299)
22. Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
23. Chinnadurai G, Vijayalingam S, Rashmi R. BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. Oncogene 2008; 27 (Suppl 1): S20-S29.
24. Mebratu YA, Dickey BF, Evans C, Tesfaigzi Y. The BH3-only protein Bik/Blk/Nbk inhibits nuclear translocation of activated ERK1/2 to mediate IFNgamma-induced cell death. J Cell Biol 2008; 183: 429-439.
25. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-362. (Pubitemid 43128863)
26. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993; 260: 85-88. (Pubitemid 23122749)
27. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE 2009; 4: e4576.
28. Lopez-Crapez E, Chypre C, Saavedra J, Marchand J, Grenier J. Rapid and large-scale method to detect K-ras gene mutations in tumor samples. Clin Chem 1997; 43 (6 Part 1): 936-942. (Pubitemid 27246982)
29. Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 2004; 101: 15313-15317. (Pubitemid 39441538)
30. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood 2007; 109: 4006-4015. (Pubitemid 46641754)
31. Boyd J, Gallo G, Elangovan B, Houghton A, Malstrom S, Avery B et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 1995; 11: 1921-1928.
32. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Therapeutics 2005; 4: 443-449. (Pubitemid 40443929)
33. Marshansky V, Wang X, Bertrand R, Luo H, Duguid W, Chinnadurai G et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001; 166: 3130-3142. (Pubitemid 33117310)
34. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005; 24: 4993-4999. (Pubitemid 41129103)
35. Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G et al. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 2003; 22: 6785-6793. (Pubitemid 37372218)
36. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077-3080; discussion 3080.
37. Né el B, Lopez J, Chabadel A, Gillet G. Lithium suppresses motility and invasivity of v-src-transformed cells by glutathione-dependent activation of phosphotyrosine phosphatases. Oncogene 2009; 28: 3246-3260.
38. Eskes R, Antonsson B, Osen-Sand A, Montessuit S, Richter C, Sadoul R et al. Baxinduced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ ions. J Cell Biol 1998; 143: 217-224. (Pubitemid 28480530)
39. Fujiki Y, Hubbard AL, Fowler S, Lazarow PB. Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum. J Cell Biol 1982; 93: 97-102. (Pubitemid 12117045)